Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimecrolimus

FDA-approved product (cream, topical), marketed as Elidel, Pimecrolimus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Pimecrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimecrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimecrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Elidel-Study: Elidel in Patients With Atopic Dermatitis

    NCT00180141 · start 2005-04

    Registered record
    Registry ID
    NCT00180141
    Conditions
    Atopic Dermatitis
    Interventions
    Elidel-Creme
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionElidel-Creme
    PhasePhase 4
    Registry statusCompleted

  • Quality of Life Study in Adults With Facial Eczema

    NCT00120302 · start 2005-03

    Registered record
    Registry ID
    NCT00120302
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-03
    Completion
    2006-01
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis

    NCT00150059 · start 2004-12

    Registered record
    Registry ID
    NCT00150059
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus Cream 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-12
    Completion
    2005-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus Cream 1%
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream

    NCT00321750 · start 2004-12

    Registered record
    Registry ID
    NCT00321750
    Conditions
    Oral Erosive Lichen Planus
    Interventions
    1% pimecrolimus cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-12
    Completion
    2005-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Erosive Lichen Planus
    Intervention1% pimecrolimus cream
    PhasePhase 2
    Registry statusTerminated

  • Combination Therapy for Atopic Dermatitis

    NCT00119158 · start 2004-10

    Registered record
    Registry ID
    NCT00119158
    Conditions
    Atopic Dermatitis
    Interventions
    Combination of pimecrolimus and fluticasone; pimecrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-10
    Completion
    2005-06
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionCombination of pimecrolimus and fluticasone; pimecrolimus
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

    NCT00121316 · start 2004-10

    Registered record
    Registry ID
    NCT00121316
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-10
    Completion
    2005-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

    NCT00128245 · start 2004-09

    Registered record
    Registry ID
    NCT00128245
    Conditions
    Keratoconjunctivitis Sicca
    Interventions
    Pimecrolimus; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-09
    Completion
    2006-12
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratoconjunctivitis Sicca
    InterventionPimecrolimus; Vehicle
    PhasePhase 2
    Registry statusCompleted

  • Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis

    NCT00098189 · start 2004-07

    Registered record
    Registry ID
    NCT00098189
    Conditions
    Psoriasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-07
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis

    NCT00226707 · start 2004-07

    Registered record
    Registry ID
    NCT00226707
    Conditions
    Chronic Hand Dermatitis
    Interventions
    Pimecrolimus Cream 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-03
    Enrolment
    652

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hand Dermatitis
    InterventionPimecrolimus Cream 1%
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Elidel Cream on Erosive Oral Lichen Planus

    NCT00130572 · start 2004-06

    Registered record
    Registry ID
    NCT00130572
    Conditions
    Lichen Planus, Oral
    Interventions
    Pimecrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2007-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Planus, Oral
    InterventionPimecrolimus
    PhasePhase 3
    Registry statusCompleted

  • Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis

    NCT00148746 · start 2004-05

    Registered record
    Registry ID
    NCT00148746
    Conditions
    Moderate to Severe Atopic Dermatitis
    Interventions
    Pimecrolimus; Tacrolimus; Prednisolone; Ciclosporin A; Dermatop
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-05
    Completion
    2008-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Atopic Dermatitis
    InterventionPimecrolimus; Tacrolimus; Prednisolone; Ciclosporin A +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

    NCT00231998 · start 2004-05

    Registered record
    Registry ID
    NCT00231998
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

    NCT00372307 · start 2004-05

    Registered record
    Registry ID
    NCT00372307
    Conditions
    Vitiligo Vulgaris
    Interventions
    Application of pimecrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2004-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo Vulgaris
    InterventionApplication of pimecrolimus
    PhasePhase 2
    Registry statusCompleted

  • Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis

    NCT00117377 · start 2004-04

    Registered record
    Registry ID
    NCT00117377
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-06
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus; Placebo
    PhasePhase 4
    Registry statusCompleted

  • 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

    NCT00120523 · start 2004-04

    Registered record
    Registry ID
    NCT00120523
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus; Topical corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2010-10
    Enrolment
    2,418

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus; Topical corticosteroids
    PhasePhase 3
    Registry statusCompleted